ARCHIVES

FDA Backs Down, Releases INDs, But Revives Controversy Over Clinical Testing Guidelines

This article is from The Cancer Letter archive.

Vol. 02 No. 11 | March 12, 1976

Download PDF Visit The Full Archive

Related Articles

DCT Board Approves Recommendations For Clinical Trials; Some Controversial

November 9, 1979

FDA Declares Taxol Orphan Drug For KS; Can IVAX Break Bristol’s Exclusivity?

August 15, 1997

Cancer Prevention Fellowship Program Offers Enhancement

March 8, 1991

In Brief: President’s Request For NCI FY 1981 Budget: Same As 1980; New Clinical Study Section Option Open

December 14, 1979

In Brief: USC Norris Opens Topping Tower March 21; Postal Service To Sell Breast Cancer Stamps

March 15, 1996

NCAB Says President’s Budget Would “Seriously Damage” Cancer Program

February 12, 1999